Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Traphaco JSCSTC:TRA 82 Debt-to-EBITDA is 0.47 as of Mar. 2026, which is 81% above its 10-year median of 0.26. GuruFocus rates STC:TRA with a GF Score™ of 82/100 and a GF Value™ of ₫46,294.60 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 689 Drug Manufacturers companies, Traphaco JSC ranks better than 73.15% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Traphaco JSC's Debt-to-EBITDA or its related term are showing as below:
STC:TRA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.05 Med: 0.26 Max: 0.67
Current: 0.47
During the past 13 years, the highest Debt-to-EBITDA Ratio of Traphaco JSC was 0.67. The lowest was 0.05. And the median was 0.26.
STC:TRA's Debt-to-EBITDA is ranked better than 73.15% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs STC:TRA: 0.47
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Traphaco JSC Debt-to-EBITDA Related Terms
Traphaco JSC Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Traphaco JSC's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Traphaco JSC's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Traphaco JSC Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Traphaco JSC's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Traphaco JSC's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Traphaco JSC (STC:TRA) has a Debt-to-EBITDA of 0.47 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Traphaco JSC. This is 81% above median its historical median of 0.26. Over the past decade, Traphaco JSC's Debt-to-EBITDA has ranged from 0.05 to 0.67. According to the industry distribution chart, Traphaco JSC ranks #185 out of 689 companies in the Drug Manufacturers industry, placing it in the top 26.9%.
Is Traphaco JSC's Debt-to-EBITDA too high?
Traphaco JSC's current Debt-to-EBITDA of 0.47 is 81% above median its 10-year median of 0.26. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.67. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Traphaco JSC's value of 0.47 is 71.3% below this industry median. Based on the distribution chart, Traphaco JSC ranks #185 out of 689 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Traphaco JSC has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Traphaco JSC's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Traphaco JSC ranks #185 out of 689 companies for Debt-to-EBITDA. This puts Traphaco JSC in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Traphaco JSC's value of 0.47 is 71.3% below this benchmark. Historically, Traphaco JSC's own Debt-to-EBITDA has ranged from 0.05 to 0.67 over the past decade. While the company's 10-year median is 0.26 vs. the industry median of 1.64, Traphaco JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Traphaco JSC's current Debt-to-EBITDA of 0.47 is 71.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Traphaco JSC. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Traphaco JSC's current Debt-to-EBITDA is 0.47, which is 81% above median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traphaco JSC stock overvalued right now?
Based on GuruFocus' analysis, Traphaco JSC (STC:TRA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫46,294.60, compared to a current price of ₫37,950.00 — trading 18% below its estimated fair value. The current Debt-to-EBITDA is 0.47, which is 81% above median its 10-year median of 0.26 and 71.3% below the Drug Manufacturers industry median of 1.64. Traphaco JSC's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Traphaco JSC (STC:TRA), the current Debt-to-EBITDA is 0.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Traphaco JSC (STC:TRA) Overvalued in 2026?
Based on GuruFocus' analysis, Traphaco JSC stock appears to be undervalued.
The current stock price of ₫37,950.00 is trading 18% below its estimated GF Value™ of ₫46,294.60.
GuruFocus considers Traphaco JSC to be Modestly Undervalued.
Key valuation signals for STC:TRA:
Debt-to-EBITDA: 0.47 (81% above median its 10-year median of 0.26)
GF Value™: ₫46,294.60 vs. price of ₫37,950.00 (18% below fair value)
Industry Position: 71.3% below the Drug Manufacturers median (#185 of 689)
No single metric tells the full story. See the STC:TRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Traphaco JSC is engaged in the production and trading of pharmaceuticals, chemicals, and medical supplies and equipment. The company's products are used for nourishing the body, the Skeletal system, for hair, for eyes, the Nervous system, the Respiratory system, and Other groups.
82GF Score
Get the complete analysis for STC:TRA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:TRA has been successfully added to your 
